Erbitux
Payments companies reported to CMS as associated with Erbitux. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Erbitux, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Erbitux
These are the largest totals companies reported as associated with Erbitux. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Edmund Kopetz | Houston, TX | Medical Oncology | $5,250.00 |
| Christine Parseghian | Houston, TX | Medical Oncology | $3,967.50 |
| Guillermo Argiles-Martine | New York, NY | Medical Oncology | $1,636.11 |
| John Novak | Aurora, CO | Medical | $61.82 |
| Cesar Perez | Orlando, FL | Medical Oncology | $27.89 |
| James Shanks | Maplewood, MN | Hematology & Oncology | $18.40 |
| Kristie Elghazi | Woodbury, MN | Adult Health (Nurse Practitioner) | $18.40 |
| Chaithanya Bhaskar | Minneapolis, MN | Hematology & Oncology | $18.40 |
| Erin Sly | Rochester, MN | Nurse Practitioner | $18.40 |
| Puneet Cheema | Maplewood, MN | Hematology & Oncology | $18.40 |
Prescribed Erbitux?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.